Skip to main content

Table 1 Characteristics of colorectal cancer patients by post-diagnostic aspirin use

From: Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

 

Aspirin use in first year after cancer diagnosisa

Yes (n = 2150)

No (n = 6241)

Number

%

Number

%

Age

 < 50

13

0.6

432

6.9

 50–59

131

6.1

1113

17.8

 60–69

586

27.3

1973

31.6

 70–79

934

43.4

1876

30.1

 ≥ 80

486

22.6

847

13.6

Gender

 Men

1387

64.5

3287

52.7

Deprivation (fifth)

 1 (most deprived)

447

20.8

1039

16.6

 2

497

23.1

1272

20.4

 3

429

20.0

1263

20.2

 4

412

19.2

1361

21.8

 5 (least deprived)

365

17.0

1305

20.9

Tumour location

 Colon

1493

69.4

4227

67.7

 Rectum/rectosigmoid junction

657

30.6

2014

32.3

Dukes’ stage

 A

597

27.8

1683

27.0

 B

851

39.6

2340

37.5

 C

702

32.7

2218

35.5

Grade

 Well differentiated

82

3.8

203

3.3

 Moderately differentiated

1646

76.6

4796

76.8

 Poorly differentiated

315

14.7

968

15.5

 Missing

107

5.0

274

4.4

Treatment (within six months)

 Surgery

2020

94.0

5908

94.7

 Radiotherapy

192

8.9

679

10.9

 Chemotherapy

472

22.0

2167

34.7

Comorbidity before cancer diagnosis

 Acute myocardial infarction

300

14.0

103

1.7

 Congestive heart failure

135

6.3

94

1.5

 Peripheral vascular disease

145

6.7

80

1.3

 Cerebral vascular accident

162

7.5

141

2.3

 Pulmonary disease

207

9.6

383

6.1

 Peptic ulcer

59

2.7

151

2.4

 Liver disease

6

0.3

25

0.4

 Diabetes

290

13.5

285

4.6

 Renal disease

87

4.0

102

1.6

Statin use after diagnosis

1647

76.6

1490

23.9

  1. aRestricted to patients who survived at least 1 year after diagnosis